Sinopharm Group

What Sinopharm Group does

Sinopharm Group Co. Ltd. is China's largest pharmaceutical and medical device distributor and retailer, operating as a state-owned enterprise under China National Pharmaceutical Group. Founded in January 2003 and listed on the Hong Kong Stock Exchange in September 2009 (stock code 01099.HK), it functions as the dominant distribution channel between pharmaceutical manufacturers and end-users across the Chinese market.

The company operates four business segments: pharmaceutical distribution, medical device distribution, retail pharmacy operations, and pharmaceutical manufacturing. Its infrastructure includes a nationwide distribution network serving over 700,000 terminal customers, more than 10,000 retail pharmacy stores, and over 1,100 subsidiaries, with headquarters in Shanghai. Recent strategic actions include a USD 3 billion privatization bid for China Traditional Chinese Medicine Holdings, partnerships with MSD and Woori IO, and a leadership refresh through 2024-2025.

The business model is fundamentally B2B pharmaceutical distribution, generating revenue through the procurement, warehousing, and delivery of pharmaceutical products and medical devices to hospitals, retail pharmacies, and other institutional customers across China. Revenue for 2025 was reported at approximately RMB 575.2 billion (around USD 80-82 billion), with the retail pharmacy segment providing direct-to-consumer outlets and the manufacturing segment producing pharmaceutical products including traditional Chinese medicine. The company's scale, SOE status, and channel control across both upstream manufacturers and downstream institutional buyers position it as a structurally critical node in the Chinese healthcare supply chain.

Name

Sinopharm Group

Legal name

Sinopharm Group Co. Ltd.

Website

https://ir.sinopharmgroup.com.cn

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Sinopharm Group is China's largest pharmaceutical and medical device distributor and retailer, serving over 700,000 terminal customers and operating more than 10,000 retail pharmacies as a state-owned enterprise listed in Hong Kong.

Ownership category

akta.pro rank

Headquarters

HQ city

Changning

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Distribution: Pharmaceutical distribution is the main business segment. The company distributes pharmaceutical products, health products, and other supplies to domestic and foreign pharmaceutical and health product manufacturers, providing distribution, logistics, and other value-added services.
2. Medical Device Distribution: Distribution of medical devices in China.
3. Retail Pharmacy: Retail pharmacy network with directly operated and franchised pharmacies in major Chinese cities, with over 10,000 stores.
4. Manufacturing: Manufacturing and sales of pharmaceuticals, chemical reagents, and laboratory supplies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Sinopharm Group is a pharmaceutical and medical device distribution and supply chain services company. It distributes medicines, medical devices and healthcare products from manufacturers to hospitals, clinics and pharmacies, operates a nationwide retail pharmacy chain, and manufactures pharmaceutical products including chemical reagents and laboratory supplies for institutional buyers.

Product overview

Sinopharm Group operates as an integrated pharmaceutical and medical device distribution and retail company with four main business segments: pharmaceutical distribution (core business), medical device distribution, pharmaceutical retail (over 10,000 stores), and manufacturing of chemical reagents and laboratory supplies. The company serves as China's leading pharmaceutical and medical device distributor with the largest national distribution network.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Revenue of RMB 575.2 billion in 2025
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• MSD (Merck)coreStrategic or Co-development Partner · 9 July 2026Sinopharm Group held strategic cooperation discussions with MSD in Shanghai to strengthen collaboration in the pharmaceutical sector, building on a cooperation framework agreement signed in September 2022. The collaboration is expected to focus on drug development, distribution, and innovation.
• Woori IO Co., Ltd.minorStrategic or Co-development Partner · 19 March 2026OSR Holdings subsidiary Woori IO signed a mutual NDA with Sinopharm Group Beijing Huahong to evaluate potential regulatory, clinical, and commercial pathways for its noninvasive near-infrared glucose monitoring technology in China's diabetes market of over 140 million patients.
• Woori IO Co., Ltd.minorStrategic or Co-development Partner · 19 March 2026Sinopharm Group Beijing Huahong signed NDA with Woori IO to evaluate glucose monitoring technology commercialization in China. Sinopharm Group is China's largest pharmaceutical and medical device distributor with approximately USD 81 billion in 2024 revenue.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cardinal Health: Cardinal Health is one of the largest US pharmaceutical wholesalers with a comparable pharmaceutical distribution and medical products distribution business model, serving as a global incumbent benchmark for Sinopharm's wholesale operations.
• Walgreens Boots Alliance: Walgreens Boots Alliance operates one of the world's largest retail pharmacy networks combined with wholesale distribution, providing a comparable pharmacy retail and pharmaceutical distribution model to Sinopharm's integrated business.
• McKesson Corporation: McKesson is one of the world's largest pharmaceutical wholesalers with comparable pharmaceutical distribution, supply chain management, and healthcare services globally—operating as a broad incumbent to Sinopharm.
• CVS Health: CVS Health operates a major US pharmacy retail chain and pharmacy benefits management business alongside distribution services, making it a broad incumbent comparable to Sinopharm's integrated pharmacy retail and distribution model.
• Cencora (formerly AmerisourceBergen): Cencora is a leading global pharmaceutical distributor with comparable pharmaceutical distribution and specialty drug services, serving as a US-based broad incumbent comparable to Sinopharm's wholesale and specialty drug operations.

Direct peers

• Jointown Pharmaceutical Group: Jointown Pharmaceutical is one of China's largest private-sector pharmaceutical distributors and a direct competitor to Sinopharm, with comparable distribution, retail pharmacy, and digital healthcare operations—offering a non-SOE benchmark.
• Shanghai Pharmaceuticals Holding: Shanghai Pharmaceuticals Holding is one of China's largest state-owned pharmaceutical distributors and a direct competitor to Sinopharm, offering pharmaceutical distribution, manufacturing, and retail pharmacy services across China.
• China Traditional Chinese Medicine Holdings: China Traditional Chinese Medicine is a major Chinese medicine manufacturer and distributor; Sinopharm is currently pursuing a USD 3 billion privatization buyout, making it a strategically significant peer and acquisition target.
• China Resources Pharmaceutical Group: China Resources Pharmaceutical Group is a major state-owned pharmaceutical distributor in China and a direct competitor to Sinopharm, offering pharmaceutical R&D, manufacturing, and distribution services of comparable scale and state-owned status.
• Guangzhou Pharmaceutical Holdings: Guangzhou Pharmaceutical Holdings is a leading state-owned pharmaceutical company in southern China with significant pharmaceutical distribution and manufacturing operations, directly competing with Sinopharm in regional markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sinopharm Group